RxDoctor Payments Data

Mahmood Ali, MD

Pulmonary Disease · Orlando, FLNPI 1356359129

Payments from drug & device makers

$158,166in general payments, 2019–2025

Across 742 payments — averaging $213.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$122K
  • Sanofi US Services Inc.$21K
  • AstraZeneca$2K
  • GSK$2K
  • Philips North America LLC$2K
  • Pfizer$1K
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$13,43199%
  • Education$1381%
  • Gifts$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,166 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$585,246
Medicare patients
1,006
Services billed
6,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter314$366,433
Dupixent PenDupilumab56$208,813
Dupixent SyringeDupilumab36$141,788
Spiriva RespimatTiotropium Bromide93$106,625
Breztri AerosphereBudesonide/Glycopyr/Formoterol81$99,161
XolairOmalizumab22$69,799
Fasenra PenBenralizumab12$64,163
AdcircaTadalafil13$52,718
TezspireTezepelumab-Ekko12$51,169
Breo ElliptaFluticasone/Vilanterol75$50,424
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$37,885
SymbicortBudesonide/Formoterol Fumarate73$30,974
Ambrisentan18$22,400
Combivent RespimatIpratropium/Albuterol Sulfate12$17,728
Advair HfaFluticasone Propion/Salmeterol19$15,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,058$462,189438 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$2,359$181,304166 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$782$139,627118 claims
United Therapeutics CorporationAdcirca$104$52,71813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →